ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE
Non-Small Cell Lung Carcinoma
Bristol-Myers Squibbantibody_drug_conjugatePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
1205 Active assets in the Non-Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
Icotinib The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | BBB |
Veliparib AbbVie | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →